Premium
PROPRANOLOL IMPROVES THE IMPAIRED TSH RESPONSE TO TRH IN PATIENTS WITH AUTONOMOUSLY FUNCTIONING EUTHYROID MULTINODULAR GOITRE
Author(s) -
ELTE J. W. F.,
HAAK A.,
WIARDA K. S.,
FRÖLICH M.,
VELDE E. A.,
HEIDE D.,
QUERIDO A.
Publication year - 1982
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1982.tb03172.x
Subject(s) - euthyroid , propranolol , medicine , endocrinology , trh stimulation test , subclinical infection , multinodular goitre , hormone , thyrotropin releasing hormone , thyroid , thyroidectomy
SUMMARY Ten patients with autonomously functioning euthyroid multinodular goitre received propranolol (Inderal® Retard 160 mg daily) for 4 weeks in order to investigate whether normalization of the TRH test or an increased TSH response to TRH could be obtained by decreasing serum T3 levels. Serum T3 decreased significantly after 2 and 4 weeks of propranolol administration. Serum T4 increased during this period, although the change was only significant after 4 weeks of propranolol. T3 resin uptake did not change. The TSH response to TRH increased significantly during the administration of propranolol. Mean Δ TSH basally was 1·0, range 0–3·9 mU/1, and mean Δ TSH after 4 weeks of propranolol was 2·4, range 0–9·3 mU/1. A strong correlation was found between the increase in Δ TSH and the decrease in serum T3 after 4 weeks of propranolol. After withdrawal, Δ TSH and T3 returned to premedication levels. Our data suggest that T3 is an important factor in the impairment of the TSH response to TRH in our patients. Normalization of the TRH test was, however, not obtained. These findings support the concept of subclinical hyperthyroidism in ‘euthyroid’multinodular goitre with autonomous function.